Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials

Wang, Junqi; Lan, Qing

doi:10.1259/bjr.20160418

Cited by 19 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A literature review by Wang and Qin of randomized, controlled trials indicated that compared with antithyroid drugs, radioiodine treatment has a higher hyperthyroid cure rate, lower recurrence rate and lower incidence of adverse events. However, it was also found to carry a greater risk for the development or worsening of ophthalmopathy and for hypothyroidism (6). However, radioiodine is increasingly used as the definitive treatment of choice in most patients with hyperthyroidism (7).…”

Section: Discussionmentioning

confidence: 99%

Thyroglobulin as a possible predictor of doses radioiodine therapy in hyperthyroidism

S¹

2018

Acta Med Sal

View full text Add to dashboard Cite

Introduction According to guidelines for the management of hyperthyroidism, patients with hyperthyroidism should be treated with radioactive iodine, antithyroid drugs, or thyroidectomy. Oral administration of radioiodine is a safe and cost effective treatment option for patients with toxic multinodular goiter (TMG)/toxic adenoma (TA) or Grave’s disease (GD). The aim of the study was to evaluate the use of thyroglobulin values as a possible predictor of a dose of radioiodine therapy (RAI) in hyperthyroidism in patients GD, TA and TMG. Results The study included 105 patients (14.4 % males and 85.6% females). The average duration of the disease was 9 years. Graves’s disease is registered among 50.68%, toxic multinodular goiter among 30.83% and toxic adenoma among 18.49% of patients. Patients were divided into four groups, and they received four doses of radioiodine therapy: 10mCi, 15mCi, 20mCi and 25mCi. The values of thyroglubulin were measured before RAI, and in period of one, three and six months after the therapy. Conclusion It can be concluded that the higher average value of thyroglobulin before therapy suggests the need for administering a higher doses of RAI, so determination of thyroglobulin levels in serum, may serve as a good predictor to assist in monitoring the administered dose of RAI in patients with hyperthyroidism.

show abstract

Section: Discussionmentioning

confidence: 99%

Thyroglobulin as a possible predictor of doses radioiodine therapy in hyperthyroidism

S¹

2018

Acta Med Sal

View full text Add to dashboard Cite

show abstract

“…Among 26 included MAs, 16 [14,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] were published in English, including two Cochrane reviews [35,37], the other 10 [40][41][42][43][44][45][46][47][48][49] were published in Chinese. The median year of the publications was 2010.…”

Section: Characteristics Of Included Masmentioning

confidence: 99%

“…These three MAs were published in Chinese and two were performed by the same authors, which may limit the generalizability of the results. Furthermore, one MA [39] reported that RAI compared with ATD therapy significantly elevated the cure rate in patients with hyperthyroidism. The study included nine RCTs with a large number of patients, so the credibility of the conclusion is relatively high.…”

Section: Efficacy Of Hyperthyroidismmentioning

confidence: 99%

“…Three MAs [14,28,46] showed the relatively high relapse rate of ATD therapy in comparison with that of RAI. In addition, two MAs [30,39] reported that there was no statistically significant difference in relapse rates between ATD and RAI. However, there was a clinically significant benefit regarding the recurrence of hyperthyroidism following RAI treatment.…”

Section: Relapses Of Hyperthyroidismmentioning

confidence: 99%

See 1 more Smart Citation

Methodological Quality Assessment of Meta-Analyses of Hyperthyroidism Treatment

et al. 2017

View full text Add to dashboard Cite

Hyperthyroidism is a common condition that is associated with increased morbidity and mortality. A number of meta-analyses (MAs) have assessed the therapeutic measures for hyperthyroidism, including antithyroid drugs, surgery, and radioiodine, however, the methodological quality has not been evaluated. This study evaluated the methodological quality and summarized the evidence obtained from MAs of hyperthyroidism treatments for radioiodine, antithyroid drugs, and surgery. We searched the PubMed, EMBASE, Cochrane Library, Web of Science, and Chinese Biomedical Literature Database databases. Two investigators independently assessed the meta-analyses titles and abstracts for inclusion. Methodological quality was assessed using the validated AMSTAR (Assessing the Methodological Quality of Systematic Reviews) tool. A total of 26 MAs fulfilled the inclusion criteria. Based on the AMSTAR scores, the average methodological quality was 8.31, with large variability ranging from 4 to 11. The methodological quality of English meta-analyses was better than that of Chinese meta-analyses. Cochrane reviews had better methodological quality than non-Cochrane reviews due to better study selection and data extraction, the inclusion of unpublished studies, and better reporting of study characteristics. The authors did not report conflicts of interest in 53.8% meta-analyses, and 19.2% did not report the harmful effects of treatment. Publication bias was not assessed in 38.5% of meta-analyses, and 19.2% did not report the follow-up time. Large-scale assessment of methodological quality of meta-analyses of hyperthyroidism treatment highlighted methodological strengths and weaknesses. Consideration of scientific quality when formulating conclusions should be made explicit. Future meta-analyses should improve on reporting conflict of interest.

show abstract

“…75 years later, Wang and Qin have concluded on the basis of a meta analysis that 'Radioiodine therapy is associated with a higher hyperthyroid cure rate and lower relapse rate' than anti-thyroid drugs and they 'would recommend radioiodine therapy as the treatment of choice for patients with Graves' disease' [18]. The issues with such treatment are the side-effects of radioiodine, hypothyroidism and the potential carcinogenic effects of radiation.…”

Section: Benign Thyroid Diseasementioning

confidence: 99%

Radioiodine – the success story of Nuclear Medicine

McCready

2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials

Cited by 19 publications

References 32 publications

Thyroglobulin as a possible predictor of doses radioiodine therapy in hyperthyroidism

Thyroglobulin as a possible predictor of doses radioiodine therapy in hyperthyroidism

Methodological Quality Assessment of Meta-Analyses of Hyperthyroidism Treatment

Radioiodine – the success story of Nuclear Medicine

Contact Info

Product

Resources

About